Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Curegenix, Inc.”

9 pharma patents match "Curegenix, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 9
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 9 pharmaceutical patents matching "Curegenix, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

9 results for “Curegenix, Inc.” · 30,257 patents in full index Clear search

  1. US 10702473

    Liposome formulation for delivery of Wnt signal pathway inhibitor

    Curegenix, Inc. · Granted Jul 7, 2020 · Expires Jul 2, 2040

    granted
  2. US 10660889

    Compounds for treatment of cancer

    Curegenix, Inc. · Granted May 26, 2020 · Expires May 21, 2040

    granted
  3. US 10285988

    Compounds for treatment of fibrosis diseases

    Curegenix, Inc. · Granted May 14, 2019 · Expires May 9, 2039

    granted
  4. US 10238652

    Compounds for treatment of cancer

    Curegenix, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  5. US 10087181

    Compound as WNT signaling inhibitor, composition, and use thereof

    Curegenix, Inc. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted
  6. US 9744169

    Compounds for treatment of fibrosis diseases

    Curegenix, Inc. · Granted Aug 29, 2017 · Expires Aug 24, 2037

    granted
  7. US 9713612

    Compounds for treatment of cancer

    Curegenix, Inc. · Granted Jul 25, 2017 · Expires Jul 20, 2037

    granted
  8. US 9556144

    Compound as WNT signaling inhibitor, composition, and use thereof

    Curegenix, Inc. · Granted Jan 31, 2017 · Expires Jan 26, 2037

    granted
  9. US 8785442

    Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof

    Curegenix, Inc. · Granted Jul 22, 2014 · Expires Jul 17, 2034

    granted